In another cohort study that included 1.651.452 patients with diabetes who were prescribed GLP-1 RAs, insulin, or metformin, GLP-1 RA use was associated with a significant risk reduction in 10 obesity-associated-cancers, including HCC (HR, 0.47; 95%CI, 0.36–0.61), compared to insulin use. This evidence concerns the gene INS and diabetes mellitus.